In August 2015, Sorrento entered into an exclusive licensing agreement to develop and commercialize four, late-stage clinical biosimilar or biobetter antibodies based on Erbitux®, Remicade®, Xolair®, and Simulect® for the North American, European and Japanese markets from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.  Each of these four antibody programs has already completed Phase 3 clinical studies in China.

Sorrento BioSimilar mAb

We look at our Mabtech collaboration as a transformational event for Sorrento and are excited about its potential to complement our expanding and deep biologics portfolio
– CEO Henry Ji

These biosimilar antibodies are:

  • cetuximab targeting the epithelial growth factor receptor (EGFR)
  • infliximab targeting tumor necrosis factor alpha (TNF-α)
  • omalizumab targeting IgE
  • basiliximab targeting the alpha chain of the interleukin-2 receptor (IL-2Rα or CD25).

Each of the four antibodies has completed a Phase III study in China.

The combination of Sorrento’s expertise in immunotherapy and drug development with Mabtech’s experience in antibody development and commercial cGMP manufacturing positions Sorrento Therapeutics as a major player in the biopharmaceutical industry to increase access to effective biosimilars.